Translational study demonstrates patient-derived lymphoma spheroids enable rapid immunotherapy screening in refractory B-cell lymphomas, indicating potential for personalized oncology avatars.
Relapsed/refractory (R/R) B‐cell lymphomas (B‐NHL) remain incurable, with limited predictive biomarkers to guide immunotherapy. Preclinical platforms that faithfully preserve the immune context and the viability of patient samples are critically needed for relevant high‐throughput drug testing. Here, we present a 3D ex vivo platform for immunotherapy screening that generates patient‐derived lymphoma spheroids (PDLS) a scaffold‐ and matrix‐free 3D model derived from peripheral blood or lymph node biopsies of patients, including R/R follicular lymphoma, transformed follicular lymphoma, or diffuse large B‐cell lymphoma. PDLS maintain the cellular composition, T‐cell activation, and immune escape profiles of the original tumors, supporting multiplexed screening of single‐agent and combination therapies within clinically relevant time frames. This scalable model recapitulates immune–tumor cell interactions, provides rapid assessment of immunotherapy efficacy, and bridges preclinical research with clinical application in aggressive B‐cell lymphomas. By integrating spatial profiling and single‐cell RNA sequencing, PDLS can further evolve into patient‐specific 3D tumor avatars that support precision oncology approaches in aggressive B‐NHL.
No takes yet. Share an insight, caveat, or question.
Gava et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: